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Introduction
Health care resources are finite in every setting  and irrespective of  the financing and organisation of  
a country’s healthcare system, decisions on what interventions to cover and under what circumstances 
have to be made in a scientific and fair way (1). Access to good quality, affordable package of  services 
and technologies according to need is a priority.  Health technology assessment is one of  the tools for 
priority setting which “refers to the systematic evaluation of  properties, effects, and/or impacts of  health technology. 
It is a multidisciplinary process to evaluate the social, economic, organizational and ethical issues of  a health intervention 
or health technology. The main purpose of  conducting an assessment is to inform policy decision making… [and is 
applied to] medicines, medical devices, vaccines, procedures and systems developed to solve a health problem and improve 
quality of  life (2).”  Whilst developed countries may have led the way, low- and middle-income countries 
(LMICs) are increasingly beginning to develop HTA processes to assist in their healthcare decision-
making.   Indeed, the institutionalisation of  health technology assessment is moving forward in many 
countries with a growing global investment in these processes as it has emerged as an important tool 
for supporting the implementation of  Universal Health Coverage (UHC) (3).  This has been bolstered 
by commitments at a global level by the issuance of  the HTA resolutions amongst Inter-American 
countries in 2012 (4), Southeast Asian countries in 2013(5), and in the World Health Assembly in 
2014 (6) in recognising the role of  HTA and robust priority-setting processes in making fair resource 
allocation decisions and sustaining health systems’ performance (6).  Since LMICs face particularly 
limited resources and, as cost-effectiveness is an integral part of  healthcare decision-making, the value 
of  HTA to help make better resource allocation decisions is being recognised.  
The benefits concerning the link between health technology assessment and outcomes in terms of  
health improvements have, however, rarely been quantified.   We distinguish here between ‘HTA’ as a 
process at the systems level to inform priority-setting and decision-making, and ‘hta’ as an individual 
health technology assessment including evidence-based interventions, practices or policies at a practical 
level.   The focus of  our research is on the impact of  HTA as a tool for priority-setting with its explicit 
consideration of  costs and benefits.  Whilst much research has been undertaken on establishing what 
factors influence improved decision-making including good governance structures, expertise, political 
and institutional factors, resources and participation (7-10), how such influences on decision-making 
interact with local context and health systems, leading to impact on health outcomes, is less understood. 
Where evaluations have been undertaken, they mainly focus on processes or outcomes at the decision-
making level, with impact on health outcomes rarely measured.  Straus et al (11), as cited in (12), state 
“…a review of  the existing literature on HTA reveals a startling lack of  depth, particularly on the impact HTA has 
had on health-care budgets, efficiency, and on societal health outcomes….whereas the previous 10 years have been well-
spent on building the HTA/EBM infrastructure and evidence base, the next 10 should focus on the outcomes.”  Also, 
“the literature on assessment of  HTA influence is still quite limited and there is little on longer term effects on clinical 
practice and health outcomes.”(13)
Even in countries where HTA programmes are well established, evidence which identifies their 
outcomes and impact in terms of  health gains is limited.  For countries with greater capacity 
constraints, how decision-making interacts with ‘context’ leading to health outcomes is even less 
explored and arguably of  critical importance(14): “... currently insufficient evidence that the use of  priority setting 
tools improves health outcomes and reverses existing inequities...we have ample evidence that the lack of  a rational and 
transparent process generates inequity and stagnation in mortality levels.” (15)
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It is evident that significant amounts of  scare resources are invested in HTA.  It has been estimated 
that NICE depends on about 2000 external experts and spends on average £150,000 for conducting 
an HTA on each new drug as based on an invitation to tender issued by the Department of  Health in 
2009 (16).  In a recent effort to move beyond impact on decision-making, RAND Europe examined 
the impact of  the National Institute for Health Research (NIHR) HTA Programme to understand its 
potential economic benefits (17).  The NIHR HTA Programme funds research about the clinical and 
cost effectiveness and broader impact of  healthcare treatments and tests for those who plan, provide or 
receive care in the UK’s National Health Service (NHS) (18).   This evaluation focused on savings for 
the NHS and health benefits to patients converted into financial terms.  To carry out this evaluation, 
some assumptions were required, in particular, that the findings were fully implemented across the 
NHS and the impact could be wholly attributed to the HTA programme (17).  Buxton and Hanney’s 
Payback Framework (19-22), previously commissioned to assess the NIHR HTA programme’s first 
ten years (1993–2003) and recognised as the most dominant methodological framework used to 
assess the impact of  healthcare research (23), categorises benefits of  health research ranging from 
traditional knowledge production and research training and targeting, to impacts on policy and product 
development through to health and economic gains. The impacts primarily focused on the areas of  
knowledge generation, perceived policy impact and, to some extent, on practice – with the finding that 
impact on knowledge generation was more easily quantified than that on policy, behaviour or especially, 
health gain.   
The focus of  our research is to go beyond decision-making outcomes as to how informed decisions 
translate into improved implementation, ultimately leading to impact in terms of  health gains.   As 
Garrido et al (2008) (24) state “the ultimate value of  HTA in a health system depends on its contribution to 
improved health status or increased efficiency rather than to increased knowledge.  In this respect, HTA does not differ 
much from other health technologies and must be subject to the same rigorous standards of  evaluation”.  Only when 
those decisions result in implementation and practice change, can better health be achieved.  Yet, 
we know that implementation of  HTA findings is variable.  Even where best practice is laid out in 
guidelines, adoption of  those guidelines can be variable.  Several studies in the UK and beyond have 
shown that the implementation of  evidence-based guidance is uneven, even across the NHS in the UK 
despite it being mandatory within 3 months, with estimates for the level of  adoption in the range of  
25%-67% (17) (25) (26-28).  
The global expansion of  HTA, its variable implementation resulting in sub-optimal impact, the lack 
of  quantified evidence on health outcomes, along with an increasing investment in these processes at 
the systems level in LMICs, in particular, has generated greater interest from policy makers and donors 
about the value and return on investment (ROI) of  HTA.   A lack of  longer-term impact assessment 
may undermine its importance and value.   To address this, we have developed a mixed-methods 
framework to quantify the value of  HTA.  Here, we present this framework employing quantitative 
methods with more qualitative explanatory approaches.  
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Aim
This research aims to provide a methodological framework and evidence base to i) quantify the returns 
on investment in HTA and ii) produce explanatory programme theory that considers individual, 
interpersonal, institutional and systems-level components and their interactions on the mechanisms by 
which HTA impact can be optimised. 
Methods
We use a mixed-methodology aimed at building up a rich picture of  process, uptake and impact.  
We present the work as 1) a mixed methods Realist Evaluation which uses quantitative data to 
capture an empirical and credible measure of  uptake (stopping) of  a technology following an HTA 
recommendation plus qualitative data to understand what it is about the context that has led to this 
level of  implementation; and 2) an interlinked return on investment (ROI) framework which uses the 
quantitative data to estimate a return on investment in HTA.   This ROI framework will measure the net 
health benefit (NHB) returns on investment in HTA.   By employing theory-driven evaluation strategies, 
we thereby synthesis economic methods with more explanatory approaches.  
Throughout the paper, as stated above, we distinguish between ‘HTA’ as a process at the systems 
level to inform priority-setting and decision-making, ie as a tool for priority-setting with its explicit 
consideration of  costs and benefits, and ‘hta’ as an individual health technology  assessment including 
evidence-based interventions, practices or policies.  In order to get to the value of  investing in health 
technology assessment at the systems levels (hereafter, referred to as ‘HTA’), we need to look at what 
the process is delivering.  In other words, we need to quantify and aggregate the value of  individual 
health technology assessments (hereafter, referred to as ‘hta’).   Central to understanding the two levels 
is the ‘value of  implementation’ (VOImp) (29).  Value of  implementation relates directly to individual 
‘hta’s but in aggregating these analyses, we can get to the value of  ‘HTA’ at a systems level.   We will 
use case study design with purposive sampling to collect data to populate the quantitative framework as 
well as realist synthesis and evaluation to help theorise the generative forces or mechanisms that lead to 
health outcomes.  The main components or ‘building blocks’ of  the framework are presented in Table 
1 together with data requirements, their potential sources and the challenges that lie therein.   Each 
component is then discussed in detail below.
6 The Value of Health Technology Assessment: a mixed methods framework
Building blocks of HTA
impact framework
Methods Data requirements Potential data
sources
Data challenges
1. Return on 
investment (ROI) 
framework 
Decision- analytic 
modelling; costing 
of resource use.
Capital and running costs of investing 
in ‘HTA’ at a systems level.
Ministry of Health or 
local government 
audit sources, national 
accounts.
Dependent on aggregating NHBs for 
all ‘hta’ decisions made.  Willingness
-to-pay threshold value assumed.
1. Realist 
evaluation 
(RE)
- Quantitative 
Value of 
implementation 
(VOI);
Interrupted Time 
Series Analysis 
(ITS) or similar to 
provide credible 
measure of 
uptake. 
Longitudinal data on utilisation with 
time-based covariates of pre/post 
uptake of ‘hta’ (actual VOImp); total 
eligible population to receive ‘hta’, 
disease prevalence (potential 
VOImp). 
Routine administrative 
health systems 
monitoring or audit 
data, for example, 
prescribing data.
Need existence of routine health 
services monitoring to be in place to 
be able to show temporal tends in 
‘hta’ uptake (stopping) before and 
after HTA recommendation; 
prevalence of disease often 
unknown or uncertain, especially in 
LMICs.   Decision analytic model of 
the ‘hta’ into health outcomes 
(DALYs/QALYs) is undertaken as part 
of the assessment process.
1. Realist 
evaluation 
(RE)
- Qualitative 
Qualitative realist 
interviews using 
case study design
Qualitative data; realist
synthesis of the literature.
Relevant stakeholders 
in HTA.
Availability and willingness of 
stakeholders to participate; ability to 
provide insights to help refute or 
refine theories.
Table 1:  The main building blocks of  the proposed HTA impact framework
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1 Return on Investment framework
We start by defining return on investment (ROI) and express this in basic terms as:
ROI=  (Gain from investment-Cost investment)/Cost investment
Gains are expressed as a percentage of  the initial investment and so a high ROI means the investment 
gains compare favourably to the cost.   These gains are typically measured in monetary terms as a 
financial ROI, or can also be expressed in terms of  social values as a social ROI (SROI), the only 
difference being how these gains are measured as costs remain the same in both cases (30).   If  we 
were to apply the concept of  a financial ROI to HTA with its focus on maximising financial returns, 
this would necessarily mean a preference for investing only in cost-saving treatments.  Treatment 
costs stemming from the ‘hta’ would need to be offset by any net disease cost savings over the long 
term.   This is not always the case with cost-effective treatments, with new treatments usually leading to 
incremental costs and effects at the margin.  Thus, were we to apply a traditional method or focus of  
‘HTA’, we may never arrive at a positive financial return, even over a lifetime.  
Instead, if  we were to apply a SROI, the social outcomes and values of  ‘HTA’ could be maintained.  
It would be more broadly applicable to ‘HTA’ as it avoids the problem raised above.  Rather than 
monetarising these benefits as is the norm in a SROI (31), we  propose the use of  net health benefits 
(NHBs), expressing costs in terms of  their health equivalence by dividing through by the willingness-
to-pay threshold (λ) for a quality-adjusted life year (QALY), thereby combining costs (C) and effect 
into a single metric.  By employing a total net benefit approach, our framework allows for the explicit 
consideration of  the costs and benefits associated with the current level of  uptake of  an ‘hta’.   An ‘hta’ 
is considered beneficial if  it provides more overall health than it displaces as a result of  its additional 
cost.  Currently, NICE takes this value to be between £20,000 - £30,000 per QALY, though research 
would indicate it is considerably lower (32).  Any new ‘hta’ must, therefore, provide an incremental cost 
per QALY in the UK of  less than £20,000-£30,000 to maximise health subject to a budget constraint.  
This concept of  opportunity costs as expressed through the threshold is central to NHBs.  This is also 
integral to any ROI.  Slotting the NHBs metric into the original ROI equation, we can express a NHB 
return on investment (NHB ROI) as follows:
𝑁𝑁𝑁𝑁𝑁𝑁 𝑅𝑅𝑅𝑅𝑅𝑅 =  ∆𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 +  �∆𝐶𝐶𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 − ∆𝐶𝐶𝑁𝑁𝐻𝐻𝑄𝑄�/𝜆𝜆
�∆𝐶𝐶𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 − ∆𝐶𝐶𝑁𝑁𝐻𝐻𝑄𝑄�/𝜆𝜆  
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2. Realist Framework 
2.1 Realist Evaluation - quantitative data
2.1.1 Value of  implementation – individual ‘hta’  
We define the impact of  ‘HTA’ to be achieved through increasing the uptake of  net beneficial ‘hta’s 
and decreasing the uptake of  non-net beneficial ‘hta’s.  As stated above, an ‘hta’ is considered beneficial 
if  it provides more overall health than it displaces as a result of  its additional cost.  By employing a 
VOImp analysis, the objective is to convey the concepts of  potential¬ population NHBs and realised 
population NHBs.  This is depicted in Figures 1 – 2.  Implementation is shown across the top of  
the figure which equates to NHBs shown running along the bottom.  The potential population 
NHB associated with full implementation of  an ‘hta’ is quantified from the use of  decision-analytic 
modelling into long term health and cost outcomes which would normally be undertaken as part of  
the assessment process of  an ‘hta’, using the best available evidence at that time.   The net population 
health benefit of  introducing an ‘hta’ is, along with setting a cost-effectiveness threshold, a function of  
its incremental costs and effects in comparison with alternative guidance or standard care, the duration 
of  usage or validity, and the size of  the patient population served (33).   Realising a net population 
health benefit then requires using available evidence or assumptions on the degree of  uptake (stopping) 
of  the ‘hta’ (at any point in time) in order to calculate the value of  current implementation.  A shortfall 
between potential and current implementation provides evidence that current care is sub-optimal.  
Indeed, it is recognised that healthcare technologies that are deemed cost-effective (or beneficial) are 
rarely immediately implemented perfectly into clinical practice (29, 34) because of  lack of  knowledge, 
behaviour change resistance or due to wider structural factors (33).  Inefficiencies exist in healthcare 
from the under- or over-use of  beneficial interventions as less than optimal adherence implies net 
benefit forgone.   VOImp is consequently about assessing the value in increasing (decreasing) utilisation 
of  the intervention to its optimal level - the value of  perfect implementation - as weighed against the 
costs and benefits of  any implementation strategies (33). 
To what extent we can attribute the ‘HTA’ process to the uptake (stopping) of  an ‘hta’ requires a 
counterfactual as to what the level of  uptake (stopping) might have been without this.  There might 
have been some natural diffusion or decline in usage of  an ‘hta’ anyway which would reduce the overall 
value and impact of  the ‘HTA’ process itself.   To estimate the extent to which implementation would 
have happened without the ‘HTA’, we draw on methods increasingly applied to natural or quasi-
experiments where randomisation is similarly unfeasible.  In an interrupted time series (ITS) design, 
data are collected at multiple instances over time before and after an intervention to detect whether 
the intervention has an effect significantly greater than the underlying secular trend (35).   By applying 
ITS, we can evaluate the effect of  a recommendation arising from the ‘HTA’ process (the intervention) 
upon the uptake (stopping) of  an ‘hta’, accounting for pre-intervention trends.   A minimum of  
three time-based covariates are required whose regression coefficients estimate the pre-intervention 
slope, the change in level at the intervention point, and the change in slope from pre-intervention 
to post-intervention.  The key assumption is that without the intervention ie the ‘HTA process’, the 
pre-intervention trend of  the uptake (stopping) of  an ‘hta’ would continue unchanged into the post-
intervention period and that there are no external factors systematically affecting the trends (36).
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2.1.2 Value of  implementation – HTA at the systems level 
By aggregating the realised NHBs of  all ‘hta’ decisions given the current level of  implementation, or 
as we propose, by taking into account a level of  implementation attributable to the HTA process as 
measured against a counterfactual, we are able to offset these total net benefits against the total costs of  
investing in ‘HTA’ at a systems level.  Such costs would include investing in the HTA infrastructure and 
the running costs associated with personnel and resources involved in undertaking the assessment and 
appraisal of  each ‘hta’.  
Figure 3 depicts the ROI-NHB impact framework for HTA.  It shows the NHBs stemming from each 
individual ‘hta’, numbered 1-K, associated with current and full levels of  implementation. The costs of  
undertaking the assessment and appraisal process for each ‘hta’ numbered 1-K are also shown.  The 
summed NHBs associated with ‘current’ and ‘counterfactual’ levels of  implementation are circled, 
Figure 1:  The value of  Implementaiton (Net Beneficial ‘hta’)
Figure 2:  The value of  (Non-)implementaiton (Non-net Beneficial ‘hta’)
The Value of Implementation (Net Beneficial HTA)
NHB: Full implementation
NHB:  Current
0% 100%
Implementation
With HTA
Without HTA
NHB: Potential
NHB: Counter-
factual
Value current implementation
Value perfect implementation
NHBs
The Value of (Non-) Implementation (Non-net Beneficial HTA)
NHB: Full implementation
NHB:  Potential
NHB: Counter-
factual
0% 100%
Implementation
With HTA
Without HTA
NHB: Current
Value current implementation
Value perfect implementation
NHBs
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those being the ‘realised’ and ‘realised and attributable’ benefits of  the ‘HTA’ process respectively.  The 
expected value of  perfect implementation is the difference between the total net benefit of  an ‘hta’ with 
perfect use (full implementation) and that with its current use.  The fixed costs (CFC) of  investing in 
‘HTA’ and the running costs (C) are then summed.  These total costs associated with the ‘HTA’ process 
can similarly be expressed in terms of  their health equivalence by dividing through by the willingness-
to-pay threshold (λ).
Finally, the aggregated total costs and benefits of  ‘HTA’, both expressed in NHBs, can be directly offset 
against each other.  Net gains or losses can be expressed as a percentage of  the initial investment to 
obtain a return on investment.
2.2. Realist Evaluation – qualitative data
At the heart of  impact evaluation is a requirement to link cause and effect in order to explain ‘how’ 
and ‘why’ – as well as addressing ‘how much’ and ‘to what extent’.  Theory driven methods will be used 
alongside the quantitative framework described above to generate, test and refine explanations for a 
gap between potential and realised gains in population health.  As macro-social structures or systems 
are not amenable to being examined by experimental methods, researchers have adapted Pawson and 
Tilley’s (1997) (37) ideas of  ‘realistic evaluation’; and a ‘theory of  change’ perspective developed by the 
Aspen Institute in the USA (Judge et al., 1999).  These approaches acknowledge social programmes 
as complex, open systems where the potential for traditional evaluation methods to explain how or 
why the programme works is viewed as weak, particularly given that the variety of  variables cannot 
be controlled.  “A program theory is an explicit theory or model of  how an intervention, such as a 
project, a program, a strategy, an initiative, or a policy, contributes to a chain of  intermediate results and 
finally to the intended or observed outcomes” (38).  It can derive from formal, research-based theory 
or an unstated, tacit understanding about how things work.  Realism was a new conceptualisation 
of  program theory, valuable for addressing the complexity of  programmes(37, 39).  It is a form of  
theory-driven evaluation based on realist philosophy and which is becoming increasingly used in the 
evaluation of  complex interventions(37).  In adopting a realist perspective, we treat the process of  
‘HTA’ as a complex intervention.  There is much diversity in the role and application of  HTA.  Such 
Figure 3:  The ROI-NHB Framework for HTA impact
Fixed cost 
‘HTA’ 
infrastructure
Number of 
‘hta’s
undertaken
Cost of undertaking
each ‘hta’ process
Level of ‘hta’ implementation
Current Full Counter-
factual
Fixed costs 1 Cost ‘hta’ process 1 𝑁𝑁𝑁𝑁𝑁𝑁1𝐶𝐼 𝑁𝑁𝑁𝑁𝑁𝑁1𝐹𝐼 𝑁𝑁𝑁𝑁𝑁𝑁1𝐶𝐹
2 Cost ‘hta’ process 2 𝑁𝑁𝑁𝑁𝑁𝑁2𝐶𝐼 𝑁𝑁𝑁𝑁𝑁𝑁2𝐹𝐼 𝑁𝑁𝑁𝑁𝑁𝑁2𝐶𝐹
… …. …. …. ….
… …. …. …. ….
… …. …. …. ….
K Cost ‘hta’ process K 𝑁𝑁𝑁𝑁𝑁𝑁𝐾𝐶𝐼 𝑁𝑁𝑁𝑁𝑁𝑁𝐾𝐹𝐼 𝑁𝑁𝑁𝑁𝑁𝑁𝐾𝐶𝐹
𝐶𝐶𝐹𝑐 + ∑ 𝐶𝐶𝑘𝐾𝑘=1
λ
�𝑁𝑁𝑁𝑁𝑁𝑁𝑘
𝐶𝐼
𝐾
𝑖=𝑘
 �𝑁𝑁𝑁𝑁𝑁𝑁𝑘𝐹𝐼𝐾
𝑖=𝑘
 �𝑁𝑁𝑁𝑁𝑁𝑁𝑘𝐶𝐹𝐾
𝑖=𝑘
  
Total benefit HTA (∆NHBs)Total cost HTA (as expressed in NHBs)
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differences reflect not only differences between health systems and their financing but also how well-
developed country-specific HTA agencies and processes are, and other wider contextual issues.  Thus, 
in theorising how the basic nature of  HTA works, we need to take account that HTA is an open-ended 
intervention ie it is already customised and needs to be highly adapted to context (40).   Theorisation 
allows a greater understanding of  how programmes work and as such a realist evaluation asks not ‘what 
works?’ but ‘how or why does this work, for whom, in what circumstances?’ (37) (41).  Realist theory 
starts with the basic premise that underlying mechanisms operating in particular contexts generate 
outcomes and makes explicit use of  a ‘context-mechanism-outcome configuration’ (CMOC) to aid 
theory development.  According to realism principles, it is actors – not the programme – who make the 
outcomes possible through various mechanisms.  Programmes are understood to provide resources or 
to change contexts to which participants respond: it is the interaction between resources and response 
that creates outcomes.  Outcomes arise from a combination of  the stakeholders’ choices (reasoning) 
and their capacity (resources) to put these into practice (38, 42).
Realism works at a middle level of  abstraction, and it is likely there is relevant theory in a range of  
different sectors that could be combined or adapted and applied as to how HTA is uptaken leading to 
health outcomes in order to produce an initial program theory or hypothesis (43).  For example, we 
could potentially draw on the knowledge translation theories outlined below as to how knowledge is 
utilised as well as a growing body of  research on the barriers and facilitators to the implementation 
of  cost-effective interventions as a useful place to start to theorise the uptake, and thus impact, of  
HTA (7, 8, 34, 44-47). Battista and Hodge (48) in their ‘natural’ history of  HTA development outline 
the ways in which HTA has evolved in different health care systems around the world.  They identify 
knowledge transmission strategies to relate to HTA dissemination and implementation.  Knowledge 
transfer exchange models have also been used in capacity building for HTA initiatives .  We have 
undertaken an initial scoping of  the literature in these areas to inform our initial programme theory.   
Also forming part of  our initial realist programme theory, is a theory of  change produced as part of  
the monitoring work of  the international Decision Support Initiative (iDSI) , a global partnership of  
leading government institutes, universities and thinktanks established in 2013 to support policy makers 
in priority-setting for UHC.  The iDSI theory of  change (ToC) shows the central processes by which 
change comes about; it states that combining demand-driven support and policy-informed knowledge 
products with institutional and procedural support would encourage better decisions about the use 
of  resources for health.  Rather than developing an HTA agency in and of  itself, ‘institutionalising’ 
priority-setting and HTA is about the importance of  developing accepted norms and rules, and 
sustaining effective working relationships between relevant policymakers and research institutions(49) 
.  This recognises that the successful implementation of  evidence-based decisions depends, in large, on 
the decision-making processes itself  and, as such, is necessary – though not necessarily, sufficient – to 
facilitate an impact in terms of  health gains.  IDSI are concerned with the initiation context for HTA, 
focusing on ‘institutional’ aspects around achieving ‘better’ recommendations or decisions, whilst the 
work presented here is about diagnosing the implementation context, targeting those ‘institutional’ 
characteristics involved in getting those recommendations or decisions into practice – its receptiveness 
and ‘readiness’ for change.  Both contexts are closely aligned and influence each other.
Realism is complementary approach that focuses on one or more causal mechanisms in a program 
theory and explores what it is about the program that makes this causal mechanism work (38).  We 
shall produce a number of  CMOCs based on iDSI’s ToC key assumptions as to how this, in turn, 
leads to health outcomes, namely; decisions are implemented; health practitioner behaviour follows 
evidence and policy; beneficiaries choose to access healthcare when it is available; lack of  healthcare 
or poor quality of  healthcare is a key driver for poor health outcomes.  Empirical testing would be 
required, necessarily involving a thorough review of  current evidence, as well as the collection of  
primary data.  A realist review is a theory-led approach to knowledge synthesis that provides an 
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explanatory analysis aimed at discerning what works, for whom, in what circumstances, how and why 
(37).   Realist evaluation, on the other hand, is a form of  primary research.  We propose to do both 
by collecting primary data following a secondary analysis in order to provide a continuing test of  the 
same theories with two quite different bodies of  data (secondary and primary)(50).  Analysis of  all data 
collected would be undertaken using realist evaluation principles of  extracting context-mechanism-
outcome configurations of  variables at play, and iterative, participative and collaborative approaches to 
interpretation.  A protocol for our realist evaluation describing the proposed process of  theory-building 
and refinement has been produced separately.  
2.2.1 Realist approach – ‘hta’
As stated above, we are dealing with both ‘hta’ as the intervention and ‘HTA’ at a systems’ level.  Both 
are potentially complex, operate at different levels and likely to interact.  To make a broader assessment 
of  the role of  HTA in an entire health system, we need to understand the value of  what that process is 
actually delivering.  Given the value of  ‘HTA’ is dependent on the implementation of  an intervention 
or technology itself, this is about understanding how well an ‘hta’ works in any given context.  How far 
along the implementation path we get (Figures 1-2) depends on this theory element.   Implementation 
science,  which is ‘the study of  methods to promote the adoption and integration of  evidence-based 
practices, interventions and policies into routine health care and public health settings’ (51), emerged in 
the wake of  evidence-based medicine.  It relates in our case at the level of  implementing an individual 
‘hta’ (52).   Formal theories from this field could include, for example, those of  socio-cognitive 
behaviour change.
2.2.2 Realist approach – HTA at the systems level
A realist lens is equally valid applied to ‘HTA’ as a process at the systems’ level, albeit perhaps at a more 
abstract level.    Policy implementation is the process of  carrying out a government decision (Berman, 
1978) and formal theories from this field which apply to more macro or meso institutional levels to 
inform our theorising could include ‘the Diffusion of  Innovations’, Governance Theory, Institutional 
Theory and network governance (52).   Such theories are broadly about the interplay and tensions 
between knowledge, power and social control, the premise being that organisations do not make 
decisions but people with biases, motives and histories make the decisions but are required to do so 
within the confines of  power structures (like organisations and governments).  This is congruent with 
the philosophy of  realist evaluation.
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Discussion
We present here a methodological framework to quantify the impact of  HTA.  None of  the methods 
discussed are novel per se – although realist evaluation is a relatively new approach to evaluation in 
healthcare and an innovative way to systematically review the literature pertaining to HTA outcomes 
as this is the first time, as far as we are aware, such an approach has been applied to this field.  The 
innovation comes, rather, from their combined use with the objective to calculate the return in 
investment in HTA.   We emphasise that we are not questioning the intrinsic logic of  HTA but rather 
how, via its effective uptake, it leads to impact in health gains.  Indeed, a mid-term review of  iDSI  
last year highlighted the need to look beyond guideline development to implementation mechanisms.  
Implementation is context specific, and realism as an approach to developing programme theory is 
particularly relevant as it focuses specifically on the influence of  context because causal mechanisms 
are activated only in favourable conditions.  We will use this to explore whether HTA can produce the 
intended impacts on health without assistance from re-theorising the programme or an injection of  
additional resources.    
There have been several impact evaluations of  HTA or HTA research to-date although Lavis (53) 
suggests that moving beyond impact on decision-making to health, economic and social outcomes is 
best left to a focused evaluation of  that specific intervention or policy:  “Moving beyond decision-making 
outcomes to health, economic and social outcomes, however, is almost certainly asking too much.  Research organisations 
simply want to know whether the research knowledge that they produce is having an impact on decision making.  
Tracing the complex pathways though which informed decisions translate into improved implementation or performance 
and ultimately into better health is best left to stand-alone research initiatives (cited Lavis 2002).  The same can be 
said of  economic and social outcomes.”   We would draw a parallel with this given the requirement in our 
framework to evaluate and aggregate the impact of  ‘hta’s in order to get to the value of  the ‘HTA’ 
process.  Most evaluations to-date have made use of  qualitative methods (54).  The findings of  a NIHR 
systematic review (55) support the continued use of  the Payback Framework as proposed by Buxton 
and Hanney to measure the impact of  health research (20) (19) (22).  The payback approach has been 
identified too as a key framework for measuring HTA impact as based on a review of  HTA impact 
models (54).  It has five categories of  impact:  knowledge production, research targeting and capacity 
building, informing policy and product development, health and health sector benefit, and broader 
economic benefit.  Others have added additional levels of  impact to their work (56).    A conceptual 
model developed for assessing the impact of  HTA in the Austrian healthcare system (54) used multi-
dimensional aspects of  impact,  namely, awareness, acceptance, policy process, policy decisions, clinical 
practice, outcomes and enlightenment based on indicators developed by Gerhardus et al (24) and Weiss’ 
theory of  research utilisation (57).  This model did not address health outcomes due to methodological 
limitations, and the authors make the recommendation that further research should address the 
methodology on how to improve impact measuring, in particular the relationship between HTA and 
the overall improvement of  health (care systems).  Indeed, Jacob and McGregor, in one of  the earliest 
HTA impact frameworks (58), define the impact of  health technology assessments so as to “influence the 
diffusion and use of  health technology in such a way as to increase the efficiency of  the health care system (by increasing 
its effectiveness or reducing its costs)”.  Using interviews, questionnaires and data banks, they estimated the 
impact of  21 HTA reports on policies and technology diffusion and utilisation, and found cost-savings 
into the millions through systematic documentation of  its effects.  RAND Europe examined the UK’s 
NIHR Health Technology Assessment Programme, 2003-2013 (59), with a separate report assessing the 
potential economic returns (17).  Assuming 100% implementation and full attribution of  the outcomes 
to the HTA programme, they concluded that 12% of  the calculated potential net benefit would cover 
the total cost of  the HTA Programme from 1993 to 2012.  NICE have also carried out audits of  the 
implementation of  its guidance as published in its, now archived, Evaluation and Review of  NICE 
Implementation evidence (ERNIE) database  but the use of  simple before-and-after measures, as 
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applied here and by others too (54), does not provide a credible measure of  uptake.
We aim to address some of  the methodological limitations above; we do not stop at full 
implementation, we include ‘negative’ decisions ie not just those which could offer benefits if  
introduced in the NHS, either by saving costs or by improving health through better treatment, and 
critically, we construct a counterfactual.   Ideally, we would find a sector unaffected by the HTA to 
make such a comparison but as groups get increasingly non comparable threats to internal validity 
become more plausible.  Alternatively, we propose drawing on quasi-experimental methods to construct 
a ‘no treatment’ control.   In particular, we propose the use of  those quasi-experimental methods 
which would enable us to a) find variation over time and b) where aggregated data is more likely to 
suffice as HTA is an area-based intervention.   Interrupted time series analysis (ITS) (35) is used in 
quasi-experiments where randomisation is unfeasible and which can provide an estimate of  attribution.  
Additionally, ITS can also include looking at the before and after intervention outcomes for another 
area (the ‘control area’) where the intervention did not take place.  This includes the difference-in-
difference method or the more sophisticated synthetic controls approach (60).  Each of  these methods 
would allow us to explore any temporal change of  the uptake of  an ‘hta’ following an ‘HTA’ decision, 
using either uncontrolled or controlled pre and post measures. Other quasi-experimental methods, such 
as regression discontinuity design (61) cannot be applied as we do not have individual level variation. 
Similarly, matching treatment and controls on selected individual characteristics or scoring them on 
a combination of  variables using propensity scores is also not applicable here (62).  Interrupted time 
series has been used previously by Sheldon et al to explore temporal variation in the implementation of  
HTA guidance where rates of  prescribing and the appropriate use of  procedures and medical devices 
relative to evidence based guidance including both stopping and uptake messages was estimated (63).   
Their findings as to whether HTA guidance had a discernible additional effect over and above the 
natural diffusion of  technologies was mixed.   
The natural diffusion of  technologies has been shown to follow an S-shaped implementation curve 
as predicted by Diffusion of  Innovation theory (64).   In applying this theory, Yates (65) highlights 
the importance of  both “macro theory (systemic adoption, that is, organisational and structural 
change) and micro theory (individual change)” (38), a distinction we make too, as does a realist 
approach which focuses its explanatory power on individual’s decisions and actions, as well the wider 
environment.   Practically, the construction of  a counterfactual to take into account the natural 
diffusion (stopping) of  a health technology is perhaps the most challenging aspect of  this research.  
Whilst ITS was successfully used previously to assess the implementation of  NICE guidance (63), it no 
longer makes sense to use this on contemporary NICE guidance as these processes have now become 
institutionalised with HTA recommendations made predominantly on newly licensed ‘hta’s.  This means 
there is fewer data prior to the HTA decision on prescribing levels and usage against which to measure 
the effect or influence of  the HTA recommendation.  Indeed, Sheldon et al applied this method prior 
to NICE recommendations becoming mandatory in 2004.  However, in LMICs, the intended focus of  
our impact framework and where these processes have not yet been institutionalised, there should be 
more data to be able to apply such methods as Sheldon et al did when NICE was still only advisory.  
Finally, we build on such existing work by incorporating these estimates of  uptake into a larger ROI 
framework in order to show impact in NHBs.
As ITS can only infer causality and produces an average measure of  effect using, in this case, 
aggregated data, we also bring in realism for a more explanatory, theory-building approach.  How 
congruent or not a counterfactual is to realist thought is a matter of  recent debate due to the potential 
conflation of  “successionist” and “generative” causation as randomised controlled trials or quasi-
experiments attempt to isolate cause to that of  the intervention alone by controlling out context ie the 
very things that realists view to be key in explaining an intervention’s success or value .  A positivist or 
successionist paradigm, rather than explaining those causes, controls for them to isolate that one cause 
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ie it is deemed possible to control for and test in that open system.  The question is can we ignore those 
causes?  Causal inference is also an important part of  program theory evaluation in order to be able 
to draw conclusions (38).  Realist inquiry is operationalised through investigating generative causation 
via the CMO heuristic.  Generative causation is understanding what underpins outcomes.  Outcomes 
are the product of  a context-mechanism association, with the nature of  the context-mechanism 
association dependent upon the architecture of  the programme in question (40).  By conceiving 
of  programme mechanisms as ‘reasoning and resources’ ie the (new) resources, opportunities or 
constraints that the programme or intervention – in our case, the ‘HTA’ process - introduces and 
‘reasoning’ (for example, trust-building, motivation to act, realisation of  knowledge) as to how people 
react in response to those resources which is influenced by context (42), there is always an interaction 
between context and mechanism.  It is that interaction which creates outcomes (66).  The degree to 
which HTA recommendations are taken up is observable and, therefore, lies at the empirical level.  
Mechanisms, in the sense that realists use the term, are underlying causal processes that cannot usually 
be directly observed.  As randomisation is unfeasible by the nature of  our intervention, we conceive 
our drawing upon natural experiment methodology (ie utilising a measure of  effect as generated by a 
‘successionist’ design) as also involving an attempt to understand the generative mechanisms entailed in 
the intervention, its natural and social context as well as those possessed by the actors involved so that 
in addition to measuring its impact, we believe a realist approach could be fruitful.  Realism is a broad 
methodological church(67); exploring how these successionist and generative paradigms may work in 
tandem is another novel aspect to this research. 
Indeed, we recognise there is such a big leap between ‘HTA’ and better health; it is a complex process, 
dependent on many assumptions about local factors and systems, including linkage between decisions 
and budgets, delivery, implementation and data accuracy – and, alluding to realism, mechanisms.  As 
Gilson et al state:  “Bringing about effective policy change does not simply require good technical design or using evidence 
to generate policy but must always involve clear attention to the processes by which change is brought about, including 
concern for the values and interests of  the actors with potential to block or subvert policy development and implementation, 
and for the discourses surrounding policy change processes”(44).   “This suggests the need for policy managers to have a 
better understanding of  the processes of  policy development, including insight into the roles of  stakeholders, their interests, 
and interactions with the health system context. However, analysis of  health policy is rarely recognized and applied in 
developing countries’ academic institutes and health administrative authorities.”(44, 68).
Finally, as the standard form of  cost-effectiveness analysis is indifferent to the distribution of  health 
and economic outcomes, there is a need to take account of  equity in any value of  ‘HTA’ framework.   
Extended cost-effectiveness analysis (ECEA) was developed to address health policy assessment, 
specifically to evaluate the health and financial consequences of  public policies in four domains: (1) 
the health gains; (2) the financial risk protection benefits; (3) the total costs to the policy makers; and 
(4) the distributional benefits (69).  Distributional cost-effectiveness analysis (DCEA), similarly looks 
at the distribution of  costs and benefits but it additionally accounts for the distribution of  opportunity 
costs and weights the trade-off  between health and the inequality reduction objective (70).    Instead 
of  a traditional CEA, the potential incorporation of  ECEA would account for financial risk, whilst 
DCEA could account for the distribution of  opportunity costs and quantify the trade-off  of  health and 
inequality (71).   
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Limitations/challenges
We evidence outcomes using (a continuum of) ‘uptake’ as a proxy for modelling impact on health.  We 
acknowledge that implementation does not equal impact.  We also limit the framework to those benefits 
resulting from the ‘hta’s being assessed and not from the process of  undertaking ‘HTA’ itself, although 
we do include its associated costs.  We recognise there are likely to be other externalities (both intrinsic 
and instrumental benefits) to arise from ‘HTA’, for example, better information, better administration 
and better payment mechanisms.  We purposively do not consider other externalities or spill-over 
effects arising from the HTA process in order to limit the scope.   Furthermore, our understanding is 
that the impact of  ‘HTA’ on health outcomes is the major gap in the literature.  
Operationalising the framework to assess the return on investment of  an entire country’s HTA 
programme is unlikely to be feasible.  Practically, we can only undertake illustrative case studies.  RAND 
restricted its evaluation to 10 HTA-funded projects framed within, presumably, the more clearly defined 
boundaries of  an audited research programme.   However, we can scale-up case studies to calculate 
how many ‘hta’s may need to be undertaken in order to get a positive return on investment.  
Conclusions
We envisage the use of  this research to support learning and to help optimise the impact of  ‘HTA’ 
in an era of  investment and expansion, in particular, into LMICs, through better understanding of  
its translation into health outcomes and estimates of  its value for money.  In particular, for LMICs, 
we want them to have a forward-looking model in the way that high-income countries have perhaps 
taken implementation and outcomes for granted.  We envisage this research, by synthesising economic 
and more qualitative methods, will provide a framework to quantify the value and impact of  HTA on 
health and economic outcomes, as well as evidence informed theory and recommendations to produce 
guidance as how to do ‘HTA’ by context in order to optimise its impact on health.
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The International Decision Support Initiative (iDSI) is a global network of  health, policy 
and economic expertise, working to achieve Universal Health Coverage and the health 
Sustainable Development Goal (SDG 3). We support countries to make better decisions 
about how much public money to spend on healthcare and how to make that money 
go further. We believe everyone should have fair access to health, receiving the right 
treatment and the right medicines at the right time.
A global network
iDSI forges regional and global partnerships that share the knowledge and support needed to achieve 
real world health gains. We focus on building institutional knowledge within existing health systems so 
countries can lead their own progress towards UHC.
Evidence-based decision making
Our work is underpinned by robust evidence, analysis and decision-making that policymakers, funders 
and researchers can use to balance trade-offs between different policy options and model potential 
results to make the best choice available. As a result, health ministries are equipped to make persuasive 
demands on public and donor spending that will save lives.
Long-term partnerships
Our work focuses on building the skills and expertise of  those involved in national health systems so 
they can make the best use of  finite resources to solve problems for current and future generations. 
As this expertise grows, we facilitate regional cooperation to increase contextual knowledge and skills 
sharing that will improve the impact and value of  healthcare spending.
Our values
• Everyone should have fair access to health, receiving the right treatment and the right 
medicines at the right time.
• Health systems need to develop and maintain their own skills so they can make the best use of  
finite resources to solve problems for current and future generations.
• Sustainable and progressive health systems are only possible when they engage and involve 
those with a stake in its success, from the public through to funders.
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